Skip to content

The Influence of Genetic Polymorphism on Dose- Dependent Analgesic Response and Safety to Propofol in General Anesthesia

The Influence of Genetic Polymorphism on Dose- Dependent Analgesic Response and Safety to Propofol in General Anesthesia

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07543523
Enrollment
159
Registered
2026-04-22
Start date
2025-04-01
Completion date
2027-04-01
Last updated
2026-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Analgesia

Brief summary

This study investigates the influence of genetic polymorphisms in key drug-metabolizing enzymes-CYP2B6, CYP2C9, and UGT1A9-on the individual response to propofol, a widely used intravenous anesthetic, in patients undergoing general anesthesia. Despite propofol's fast onset and favorable recovery profile, significant inter-individual variability exists in its dosing requirements, sedation depth, and adverse effects. Such variability is believed to arise in part from genetic differences that affect drug metabolism and action. This research focuses on identifying how specific gene variants, particularly those linked to poor or altered metabolizer phenotypes, influence clinical outcomes like induction time, recovery time, and safety profiles during anesthesia.

Detailed description

Focusing on the Pakistani population, this research seeks to fill a gap in regional pharmacogenetic data, which is limited but critical for optimizing patient care. By identifying associations between genetic profiles and anesthetic responses, the findings could support the development of personalized anesthesia protocols, improving drug safety and effectiveness. This project has great potential to advance precision medicine in anesthesiology by enabling more personalized therapeutic strategies that are guided by each patient's distinct genetic makeup.

Interventions

DIAGNOSTIC_TESTPropofol Group

Propofol will be administered according to the standard protocol, adjusted to each patient's condition and characteristics

COMBINATION_PRODUCTIsoflurane Group

Isoflurane will be used as an inhalational aesthetic

Sponsors

Superior University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No

Inclusion criteria

* Female \& males aged 18-60yrs * ASA grade 1 \& II * Patient enrolled for elective surgery * BM1 \<35

Exclusion criteria

* History of drug allergies * Any chronic disease such as hepatic, psychiatric \& kidney disease. * History of drug intake (opioids, analgesics) * History of smoking, alcohol or drug addiction.

Design outcomes

Primary

MeasureTime frameDescription
Propofol therapeutic outcomes24 MonthsProduces prompt hypnosis (within 40 seconds) and allows for rapid awakening upon discontinuation (10-30 min)

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 23, 2026